Beta Drugs Limited Stock Analysis

Exceptional gross margin expansion of 700 basis points to 59% in Q3 FY26 from 52% YoY, demonstrating successful shift toward higher-margin product mix and improved pricing power / Strong own-branded sales growth of 33% YoY indicating successful market traction in oral formulations and validated product-market fit in core therapeutic areas / Stable EBITDA margins of 22% maintained despite 21% increase in employee costs, suggesting operational leverage and disciplined cost management despite strategic investments / Clear strategic positioning toward higher-margin NDDS (Novel Drug Delivery Systems) products with Methotrexate Oral Solution projected to generate INR 13 Crores in FY27, providing identified revenue catalyst

Strategic de-focus on Platin segment creating significant near-term revenue headwinds with INR 46.50 Crores FY25 contribution now declining, contributing to FY26 guidance revision from INR 420 Crores to INR 400 Crores / Finance costs doubled to INR 4.43 Crores from INR 1.87 Crores YoY due to CCD (Compulsorily Convertible Debenture) interest, materially impacting profitability trajectory and leverage profile / Export sales facing dual headwinds from tender delays and Latin America geopolitical tensions, creating uncertainty around FY27 geographic expansion targets in Mexico, Algeria, and Philippines / Flat YoY revenue growth in Q3 FY26 despite operational improvements raises execution risk on ambitious FY27 guidance of INR 530 Crores (32% growth) with 24% EBITDA margins / Significant data gaps limit visibility—no cash flow metrics, balance sheet details, debt structure, or working capital metrics provided, preventing full assessment of financial health and capital efficiency

Gross margin improved to 59% in Q3 FY26 from 52% YoY (+700 bps), showing a stronger product mix. / EBITDA remained robust at INR 19.28 crore with EBITDA margin stable at 22% despite higher operating costs. / Own branded sales grew 33% YoY, indicating traction in higher-margin oral and branded formulations. / PAT stayed positive at INR 8.51 crore with a 9.5% net margin in a quarter with flat revenues. / Management has articulated clear medium-term targets: FY27 revenue of INR 530 crore and EBITDA margin of 24%, supported by NDDS and export expansion plans.

Top-line momentum is weak in the near term, with Q3 FY26 revenue flat YoY at INR 89.58 crore and FY26 guidance reduced to INR 400 crore from INR 420 crore. / Finance costs rose materially to INR 4.43 crore from INR 1.87 crore YoY due to CCD interest, pressuring net profitability. / Employee expenses increased 21% YoY from senior hiring, creating near-term cost absorption risk if revenue recovery is delayed. / Strategic de-focus on Platins is causing a revenue gap (Platin sales INR 31.60 crore in 9M FY26 vs INR 46.50 crore in full FY25), with replacement growth still ramping. / Export revenues face execution and external risks from tender delays and geopolitical tensions in Latin America; cash flow, leverage, and liquidity metrics are not disclosed in the provided data, limiting balance-sheet visibility.

Own-branded sales demonstrated robust 33% YoY growth, indicating strong market traction in higher-margin oral formulations and successful brand penetration strategy / Gross margin expansion of 700 basis points to 59% from 52% YoY reflects improved product mix optimization and shift toward higher-value products despite flat revenue / EBITDA margins maintained at healthy 22% level with INR 19.28 Crores absolute EBITDA despite 21% increase in employee expenses from strategic senior-level hiring / Strategic investments in talent across Regulatory, Manufacturing, and QA/QC departments position the company for future product approvals and capacity scaling / Management provided clear FY27 revenue target of INR 530 Crores with 24% EBITDA margins, representing 32.5% growth from revised FY26 guidance of INR 400 Crores

Flat YoY revenue growth at INR 89.58 Crores combined with downward-revised FY26 guidance from INR 420 Crores to INR 400 Crores signals near-term growth challenges / Interest expenses surged 137% to INR 4.43 Crores from INR 1.87 Crores YoY due to CCD interest obligations, directly impacting bottom-line profitability / Strategic exit from Platins segment created revenue gap as Platin sales were INR 31.60 Crores in 9M FY26 versus INR 46.50 Crores in full FY25, requiring replacement through new products / Export sales faced headwinds from geopolitical tensions in Latin America and tender delays, creating revenue timing uncertainties and geographic concentration risk / Complete absence of cash flow and balance sheet data limits assessment of liquidity position, debt sustainability, working capital efficiency, and free cash flow generation capability / Aggressive FY27 target of INR 530 Crores represents 32.5% growth requirement with execution risk around NDDS approvals, new market registrations in Algeria/Mexico/Philippines, and Methotrexate Oral Solution launch

Gross margin expansion to 59% in Q3FY26 from 52% in Q3FY25 demonstrates improved pricing power and product mix optimization / Own branded sales grew 33% YoY indicating strong market acceptance and reduced dependency on lower-margin CDMO business / EBITDA margins maintained at robust 22% despite 21% increase in employee costs from strategic hiring in regulatory, manufacturing, and QA/QC teams / Strategic de-focus on Platins (from INR 46.50 Crores in FY25 to INR 31.60 Crores YTD Dec'25) positions company for higher-margin product portfolio / FY27 revenue guidance of INR 530 Crores represents 32.5% growth over revised FY26 target of INR 400 Crores with improved EBITDA margins at ~24% / Cash generation capability remains intact with PAT margins at 9.5% despite increased interest burden from CCD financing

Flat revenue growth in Q3FY26 compared to previous year driven by weak CDMO sales and delayed export tenders due to geopolitical tensions in Latin America / Interest expenses surged 137% to INR 4.43 Crores from INR 1.87 Crores YoY due to CCD financing, pressuring net profitability / Employee expenses jumped 21% YoY as company invested in senior-level hiring, compressing operating leverage despite margin improvements / Export sales impacted by tender delays and Latin American geopolitical risks, creating uncertainty around international revenue streams / Revenue guidance downgraded from INR 420 Crores to INR 400 Crores for FY26 reflecting execution challenges in transitioning away from Platin sales / Consolidated results include three subsidiaries (Adley Formulations, Adley Lab, Beta Research) whose financials were not independently audited, raising transparency concerns

Gross margin expanded sharply to 59% in Q3FY26 from 52% in Q3FY25, signaling better product mix and pricing quality. / Own branded sales grew 33% YoY, indicating stronger traction in higher-margin oral products. / Operating profitability remained resilient with Q3FY26 EBITDA of INR 19.28 crore and EBITDA margin of 22% despite flat sales. / The company stayed profitable with Q3FY26 PAT of INR 8.51 crore and PAT margin of 9.5%. / Management is intentionally shifting away from lower-priority Platin business (INR 31.60 crore YTD Dec'25) toward higher-margin products, a positive strategic quality move.

Top-line momentum is weak, with Q3FY26 sales reported as flat YoY despite internal segment growth. / FY26 revenue guidance was cut from INR 420 crore to INR 400 crore, indicating weaker near-term demand/visibility. / Interest expense rose materially to INR 4.43 crore from INR 1.87 crore due to CCD-related cost, pressuring net earnings. / Employee expenses increased 21% YoY due to senior hiring in Regulatory, Manufacturing, and QA/QC, limiting EBITDA margin expansion. / Export and CDMO visibility is uncertain: key tenders were pushed out, Latin America geopolitical tensions affected exports, and no additional Platin sales are expected in Q4FY26.